

Haematologica
HAEMATOL/2017/167742
Version 4

Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: A multicenter phase II trial of West-JHOG PTCL0707

Yoshinobu Maeda, Hisakazu Nishimori, Isao Yoshida, Yasushi Hiramatsu, Masatoshi Uno, Yasufumi Masaki, Kazutaka Sunami, Taro Masunari, Yuichiro Nawa, Hiromichi Yamane, Hiroshi Gomyo, Tsutomu Takahashi, Tomofumi Yano, Keitaro Matsuo, Koichi Ohshima, Shigeo Nakamura, Tadashi Yoshino, and Mitsune Tanimoto

Disclosures: Y.M.: Research funding (Chugai and Kyowa Hakko Kirin), honoraria (Chugai, Kyowa Hakko Kirin, and Bristol-Myers Squibb); H.N.: Research funding (Chugai and Kyowa Hakko Kirin); I.Y.: Research funding (Chugai and Kyowa Hakko Kirin); Y.M.: Research Funding (Chugai, Kyowa Hakko Kirin, Daiichi-Sankyo, Shionogi, Eisai, Takeda, MSD, Japan Blood Products Organization, and Pfizer), honoraria (Chugai, Kyowa Hakko Kirin, Kissei, Janssen, Bristol-Myers Squibb, Celgene, Taiho, and Eisai); K.S.: Research Funding (Takeda, Ono, Celgene, Novartis, Bristol-Myers Squibb, Daiichi-Sankyo, Sanofi, and Janssen), honoraria (Celgene); M.T.: Research funding (Chugai and Kyowa Hakko Kirin); Y.H., M.U., T.M., Y.N., H.Y., H.G., T.T., T.Ya., K.M., K.O., S.N., T.Yo.: No disclosures.

Contributions: Y.M., I.Y., Y.H., M.U., K.S., T.M., Y.N., H.Y., T.Y., K.M., and M.T. designed the study; Y.M., I.Y., Y.H., M.U., Y.M., K.S., T.M., Y.N., H.Y., H.G., T.T., and T.Y., were involved with the study conduct, enrolled patients. H.N. and K.M. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. K.O., S.N., and T.Y. confirmed the diagnoses. Y.M. wrote the first draft of the manuscript; and all authors reviewed the manuscript for scientific content and approved the final version of the manuscript.